The lawsuit escalates the conflict between drug middlemen and one of the top US antitrust enforcers, which has been scrutinizing the industry. Cigna’s Express Scripts unit called the FTC’s July
An FTC spokesman said the agency stands by its report.
PBMs manage prescription drug plans for employers and government programs. PBMs maintain they provide a necessary counterweight to unchecked power by drug companies to set prices. Yet they’ve faced growing criticism for opaque business practices.
The agency has spent more than two years investigating the PBM industry. Its interim report in
Cigna and its rivals
Cigna’s lawsuit accuses the FTC of ignoring much of the data and documents it provided the commission in favor of “unsupported innuendo” against the industry.
The agency rejected Cigna’s claims.
“This is a complicated and opaque market, and the FTC is committed to using its clear authority to help the public and policymakers understand it,” FTC spokesman Douglas Farrar said in an email.
The case is Express Scripts v. Federal Trade Commission, 24-cv-01263, US District Court, Eastern District of Missouri (St. Louis).
To contact the reporter on this story:
To contact the editors responsible for this story:
Tonya Garcia, Peter Jeffrey
© 2024 Bloomberg L.P. All rights reserved. Used with permission.
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.